DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On September 27th, 2024 With 0.264 USD Dividend Per Share
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Merck, Daiichi Lung Cancer Therapy Rejected in U.S.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Daiichi Sankyo/AstraZeneca (AZN.US) launches phase III clinical first-line treatment for EGFR mutation NSCLC in China
On May 27, according to the CDE clinical trial registration and information disclosure platform, Daiichi Sanko/AstraZeneca (AZN.US) registered on the platform to launch a new phase III clinical tropion-Lung14 study with dATO-DXD (DS-1062A/dedabotumab) to first-line treatment of patients with locally advanced or metastatic NSCLC positive EGFR mutations (registration number: CTR20241813).
The backstage Nikkei Average started with 119 yen depreciation, and Daiichi Sankyo, Nintendo, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38780.55; -119.47TOPIX; 2762.23; -4.13 [Backward Closer Overview] The Nikkei Average in the back was 38780.55 yen, 119.47 yen lower than the previous day, and started at almost the same level as the advance draw (38783.27 yen). Nikkei 225 futures during lunchtime fit well in the 38760 yen to 38840 yen range. Dollar/yen is 1 dollar = 156.60-70 yen, and yen appreciates by about 20 yen from around 9:00 a.m.
AstraZeneca, Daiichi Sankyo's Lung Cancer Drug Shows Mixed Results in Late-stage Trial
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Double Good News For AstraZeneca's Breast Cancer Drugs
Express News | Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
The Nikkei Average in the backstage started with a 297 yen increase, and Daiichi Sankyo and Mitsui E&S are high
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 37926.06; +297.58TOPIX; 2681.69; +18.16 [Backward Closer Overview] The Nikkei Average in the back was 37926.06 yen, 297.58 yen higher than the previous day, and started by expanding the range of gains from the previous closing (37780.35 yen). Nikkei 225 futures during lunchtime rose in the range of 37740 yen to 38,000 yen. The dollar and yen depreciated by about 40 yen from around 9:00 a.m. to 1 dollar = 156.00-10 yen
Daiichi Sankyo and others announced stock buybacks on 4/25
The stocks that announced share acquisition quota settings on 4/25 (Thursday) are as follows <4568>Daiichi Sankyo 55 million shares (2.9%) 200 billion yen (24/4/26-25/1/15) <6702>Fujitsu 150 million shares (8.2%) 180 billion yen (24/5/1-25/3/31) <9531>East Gas 17 million shares (4.2%) 40 billion yen (24/5/7-25/3/31) <430
Daiichi Sankyo temporarily rose by over 5%, supported by stock buybacks up to 20 billion yen and dividend increase plans for the current fiscal year
Daiichi Sankyo was bought in the back market, and there was an increase of over 5% at one point compared to the previous day. Along with the announcement of consolidated financial results for the fiscal year ending March 24 at 1:00 p.m. on the 25th, it was announced that the total number of shares acquired is 55 million shares (2.87% of the total number of issued shares excluding treasury stock) and the total acquisition amount is 20 billion yen as an upper limit. At the same time, a plan to increase the annual dividend for the fiscal year ending March 25 to 60 yen with a 10 yen increase from the previous fiscal year was also shown, and it seems that it was a support material for stock prices.
Vincerx in Selloff After Early-stage Data for Cancer Therapy
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval
AstraZeneca's Enhertu Granted Approval for HER-2 Positive Tumor-agnostic Indications
No Data